News
NMTR
--
0.00%
--
9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome
9 Meters Biopharma (NMTR) has initiated its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with short bowel syndrome ((SBS)). The Phase 2 trial,
Seekingalpha · 4d ago
BRIEF-9 Meters Biopharma Inc - Announces Initiation Of Phase 2 Vibrant Study Of Vurolenatide For Short Bowel Syndrome
reuters.com · 4d ago
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome
ACCESSWIRE · 4d ago
9 Meters Biopharma Initiates Phase 2 Trial of Vurolenatide to Treat Short Bowel Syndrome
MT Newswires · 4d ago
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will deliver a company presentati...
ACCESSWIRE · 06/09 11:30
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
 
Benzinga · 06/04 14:03
Thinking about buying stock in Progenity, 9 Meters Biopharma, Corsair Gaming, Sundial Growers, or Zomedica?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PROG, NMTR, CRSR, SNDL, and ZOM.
PR Newswire - PRF · 06/04 13:31
Merck spinoff closes higher despite neutral views; Mirati gains on Citi upgrade; more in today’s analyst action
Organon attracts neutral views on the first day of tradingMerck (MRK) spinoff focused on women’s health and biosimilars, Organon (OGN), staged a late-afternoon rally to end ~8.4% higher yesterday on
Seekingalpha · 06/04 12:23
DOCU, CLNE, KNDI and SENS among premarket gainers
Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories...
Seekingalpha · 06/04 12:21
--Citigroup Starts 9 Meters Biopharma at Buy With $3 Price Target
MT Newswires · 06/04 07:04
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will present at the Jefferies Vir...
ACCESSWIRE · 06/01 11:31
Truist sees 231% upside on 9 Meters on broader application of COVID drug
Larazotide, a drug in development from 9 Meters Biopharma (NMTR) to treat both celiac disease in adults and a rare complication from COVID-19 in children, may have broader applications, according
Seekingalpha · 05/27 13:53
9 Meters drug effective in treating rare COVID-19 complication in children
Larazotide, in development by 9 Meters Biopharma (NMTR), led to a significant drop in inflammatory mediators in an infant with multisystem inflammatory syndrome in children (MIS-C).MIS-C is a serious, rare
Seekingalpha · 05/26 18:31
9 Meters Biopharma Shares Spike Higher On Volume As Traders Circulate Press Release Originally Published At 8:30 a.m. EDT Wednesday Highlighting Publication Of Data On Larazotide For Treating Multisystem Inflammatory Syndrome In Children
- Larazotide supplied to study authors under an FDA-approved Expanded Access Program -   - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-concept
Larazotide supplied to study authors under an FDA-approved Expanded Access Program -   - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-concept · 05/26 17:24
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection
\- Larazotide supplied to study authors under an FDA-approved Expanded Access Program -\- Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-concept support for larazotide's mechanism of action ...
ACCESSWIRE · 05/26 12:30
Tri Locum Partners LP Buys Horizon Therapeutics PLC, Regeneron Pharmaceuticals Inc, ...
GuruFocus News · 05/19 19:38
Is the Options Market Predicting a Spike in 9 Meters Biopharma (NMTR) Stock?
Zacks.com · 05/19 13:33
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
This version of the release contains a corrected hyperlink.
ACCESSWIRE · 05/18 14:15
9 Meters Biopharma, Inc. Receives USAN Approval To Use Designated Nonproprietary Name Vurolenatide For Its Long-Acting GLP-1 Agonist For Short Bowel Syndrome
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names (USAN) Council has officially
Benzinga · 05/17 11:34
--Oppenheimer Adjusts 9 Meters Biopharma PT to $5.50 From $6, Maintains Outperform Rating
MT Newswires · 05/14 10:31
Webull provides a variety of real-time NMTR stock news. You can receive the latest news about 9 Meters Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About NMTR
9 Meters Biopharma, Inc., formerly Innovate Biopharmaceuticals, Inc., is a gastrointestinal platform company. The Company is focused on developing treatments for patients with rare disorders and unmet needs. Its pipeline includes drug candidates for short bowel syndrome and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis.